Immunic Presents New Phase 2 Data Supporting Vidofludimus Calcium in Progressive MS
NEW YORK, May 28, 2026 Immunic, Inc. has unveiled new analyses from its Phase 2 CALLIPER trial evaluating vidofludimus...
IL-23 Inhibitor
Advertisement
Johnson & Johnson Wins FDA Label Expansion for TREMFYA
HORSHAM, Pennsylvania, May 28, 2026 Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and...
Lilly Omvoh Shows 4-Year UC Disease Clearance Results
INDIANAPOLIS, May 5, 2026 Eli Lilly and Company has reported new long-term clinical data demonstrating that Omvoh® (mirikizumab-mrkz) achieved...
FDA Approves J&J’s ICOTYDE Oral Peptide for Psoriasis
SPRING HOUSE, Pennsylvania, USA – March 18, 2026 In a major advancement for dermatology and systemic therapies, Johnson &...
TREMFYA Sustains UC Remission Through 3 Years
STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...
Advertisements
Canada Issues Positive Reimbursement Recommendation for Skyrizi in Ulcerative Colitis
Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...
Mabwell’s 9MW3011 Achieves Positive Phase III Results in Moderate-to-Severe Plaque Psoriasis
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
AbbVie Raises 2025 Outlook as Skyrizi and Rinvoq Surge
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Advertisement
